{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}],"title":"Pre-Dose Cycle 5: positive for HACAs (n=59)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"}]}],"title":"Pre-Dose Cycle 5: negative for HACAs (n=59)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0"}]}],"title":"Post-Dose: positive for HACAs (n=61)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1"}]}],"title":"Post-Dose: negative for HACAs (n=61)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Blood samples for the assessment of antibodies against rituximab (HACAs) were drawn pre-dose at Cycle 5 and Cycle 6 in Part 1 and at each follow up visit until 24 months after the last dose.","groups":[{"description":"Participant could have been enrolled any time during treatment with rituximab IV in combination with FC before Cycle 5. Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 1 or Day 0 (according to local practice) Cycles 2-5: IV rituximab 500 mg/m\\^2 on Day 1 Cycle 6: SC rituximab 1400, 1600 or 1870 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 1: Rituximab SC"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Population (SAP): all participants who received at least one dose of study medication, whether prematurely withdrawn from the study or not. This included 8 participants that did not receive SC rituximab. n = number of participants analyzed.","reportingStatus":"POSTED","timeFrame":"Predose at Cycles 5 and 6 and at each follow up visit until 24 months after the last dose","title":"Part 1: Percentage of Participants With Anti-Rituximab Antibodies","type":"SECONDARY","unitOfMeasure":"percentage of participants"}